Patents Assigned to BAYER AS
-
Publication number: 20230117034Abstract: The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 9, 2020Publication date: April 20, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BOEMER, Naomi BARAK, Philip LIENAU
-
Publication number: 20230121195Abstract: The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 12, 2022Publication date: April 20, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Ilona GUTCHER, Ulrike RÖHN, Norbert SCHMEES, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Horst IRLBACHER, Michael PLATTEN
-
Patent number: 11630965Abstract: A reader system for reading information on at least one identification tag associated with a syringe connected to a fluid injector has a detector and a background screen spaced apart from the detector such that at least one of the at least one identification tags is positioned in an optical path between the detector and the background screen when the syringe is connected to the fluid injector. The reader system further has an illumination system configured for illuminating at least a portion of the background screen. The detector is configured for detecting and decoding the at least one identification tag. Methods for reading information on at least one identification tag associated with a syringe are also described.Type: GrantFiled: April 9, 2021Date of Patent: April 18, 2023Assignee: BAYER HEALTHCARE LLCInventors: Christopher Capone, Jaroslaw Wlodarczyk
-
Patent number: 11628088Abstract: The present invention relates to ultrasonically detectable intrauterine systems and to a method for enhancing ultrasound detection of these systems. An intrauterine system having an inert metal coating on at least part of the body of the intrauterine system or at least one inert metal clip, pin, ring or sleeve fixedly positioned on the body of the intrauterine system is described.Type: GrantFiled: December 12, 2014Date of Patent: April 18, 2023Assignee: Bayer OYInventors: Taina Tjäder, Sara Heinonen
-
Patent number: 11628433Abstract: A dispensing device includes a housing having at least one pressure chamber, having a supply opening for the supply of liquid into the pressure chamber and having a multiplicity of conduits between the pressure chamber and an external side of the housing, there being situated in each of the conduits a tube, the first end of which protrudes into the pressure chamber and the second end of which protrudes out of the housing on the external side.Type: GrantFiled: December 14, 2017Date of Patent: April 18, 2023Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Schade, Mike Küster, Klaus Ochmann, Michael Harnau, Karl-Hermann Koeching, Nils Burkhardt, Bernd Kalthof, Linn Schneider, Georg Schmidt
-
Publication number: 20230112499Abstract: The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and poType: ApplicationFiled: December 14, 2020Publication date: April 13, 2023Applicant: Bayer AktiengesellschaftInventors: Olaf PANKNIN, Frank SACHER, Nicole SCHMIDT, Gernot LANGER, Katrin NOWAK-REPPEL, Reinhard NUBBEMEYER, Sabine PILARI, Antje ROTTMANN, Hideki MIYATAKE ONDOZABAL, Holger SIEBENEICHER, Antonius TER LAAK, Hana CERNECKA
-
Publication number: 20230113037Abstract: The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 10, 2020Publication date: April 13, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Julien LEFRANC, Norbert SCHMEES, Ludwig ZORN, Robin Michael MEIER, Simon Anthony HERBERT, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Mátyás GORJÁNÁCZ, Christina KOBER, Bernd BUCHMANN, Stephan BÖHME, Ulrich BOTHE, Michael PLATTEN, Daniel BAUMANN
-
Publication number: 20230115270Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.Type: ApplicationFiled: November 5, 2020Publication date: April 13, 2023Applicants: Bayer Aktiengesellschaft, Bayer AktiengesellschaftInventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Lisa DIETZ, Magdalena PLATZK, Daniel MEIBOM, Philipp BUCHGRABER, Niels LINDNER, Eva Maria BECKER-PELSTER, Carsten SCHMECK
-
Patent number: 11623944Abstract: The present invention relates to a composition comprising a biologically pure culture of a fungicidal Paenibacillus sp. strain comprising a variant fusaricidin synthetase lacking a functional adenylation domain in the third module. The present invention also provides a composition comprising a biologically pure culture of a fungicidal Paenibacillus sp. strain or a cell-free extract thereof comprising at least one Paeniserine and at least one Paeniprolixin. Also provided are isolated compounds and methods of treating a plant to control a plant disease with the disclosed compositions and compounds.Type: GrantFiled: October 31, 2019Date of Patent: April 11, 2023Assignee: Bayer CropScience LPInventors: Jeremy Beau, Daniel M. Joo, Patrick Schwientek, Colleen S. Taylor, Bjorn A. Traag
-
Publication number: 20230106032Abstract: The present invention provides compounds of general formula (I): in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 5, 2021Publication date: April 6, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BÖMER, Naomi BARAK, Philip LIENAU
-
Patent number: 11617727Abstract: Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 wt. % menthol; from 4 to 8 wt. % camphor; from 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.Type: GrantFiled: April 23, 2020Date of Patent: April 4, 2023Assignee: Bayer Healthcare LLCInventors: Debanjan Das, Emanuel Vizzotti, Thomas Dann, Renee Nelson, Courtney C. Haynes, Soundarya Vaithianathan, Reginald Bradley, Reinhard Walter, Gerard Meisel
-
Patent number: 11618735Abstract: The present invention relates to a novel crystal form of the monosodium salt of foramsulfuron, a method for preparing this crystal form, use thereof in agrochemical formulations and also particular compositions, mixtures or agrochemical formulations comprising this crystal form, and also a novel monomethanol solvate of the monosodium salt of foramsulfuron.Type: GrantFiled: August 13, 2019Date of Patent: April 4, 2023Assignee: Bayer CropScience AktiengesellschaftInventors: Stefan Antons, Britta Olenik, Martin Krueger
-
Patent number: 11617751Abstract: The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.Type: GrantFiled: December 20, 2012Date of Patent: April 4, 2023Assignee: BAYER PHARMA AGInventor: Kristina King
-
Patent number: 11617792Abstract: The invention relates to pharmaceutical compositions in liquid form comprising pradofloxacin in an aqueous solution and citric acid or thioglycerol as antioxidants.Type: GrantFiled: August 20, 2020Date of Patent: April 4, 2023Assignee: Bayer Animal Health GmbHInventors: Iris Heep, Patrick Billian
-
Publication number: 20230100584Abstract: The invention relates to the development of formulations, preferably for biologically active substances. The aim of the invention is to provide a method, a computer system, and a computer program product for predicting at least one property of at least one formulation using a prediction model which has been trained to predict formulation properties by means of a monitored learning process using reference data.Type: ApplicationFiled: February 18, 2021Publication date: March 30, 2023Applicant: Bayer AktiengesellschaftInventors: Holger DIEDAM, Johanna ANLAHR, Heike SKÖTSCH, Matthias ERBER
-
Patent number: 11612689Abstract: An adapter for releasably attaching a syringe to an injector. The adapter comprises a mounting mechanism positioned at a rear end of the adapter to mount the adapter in a desired position relative to a front wall of the injector; and a syringe carrier section adapted to seat at least a portion of the syringe. The syringe carrier section defines a first opening on a top thereof to allow placement of the syringe therein from the top and a second opening in a rear section thereof to allow the drive member of the injector to communicate forward force to the plunger. A cover portion extends over a rearward end of the first opening and has a first end configured to abut the flange of the syringe when the syringe is positioned within the syringe carrier section.Type: GrantFiled: November 11, 2020Date of Patent: March 28, 2023Assignee: BAYER HEALTHCARE LLCInventors: Molly Bingaman, Erin Novickoff, Patrick O'Rourke, Stephen Schulte
-
Patent number: 11613522Abstract: The invention relates to 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides of general formula (I) and to their agrochemically compatible salts (I) as well as to the use thereof in the field of plant protection.Type: GrantFiled: June 11, 2018Date of Patent: March 28, 2023Assignees: Bayer Aktiengesellschaft, Bayer CropScience AktiengesellschaftInventors: Olaf Peters, Klaus Bernhard Haaf, Guido Bojack, Katherine Rose Law, Anu Bheemaiah Machettira, Hansjoerg Dietrich, Elmar Gatzweiler, Christopher Hugh Rosinger, Elisabeth Asmus
-
Patent number: 11607489Abstract: A fluid injection system including a graphical user interface, a fluid control module operatively connected to the graphical user interface, a monitoring control module provided in at least one of the graphical user interface and the fluid control module, a fluid injector operatively connected to the graphical user interface and the fluid control module, at least one fluid path set in fluid communication with the fluid control module, and a hemodynamic monitoring system operatively connected to the fluid path set and the monitoring control module. The hemodynamic monitoring system may be configured to receive electrical signals regarding pressure waves formed in medical fluid directed through the fluid path set based on a location of the fluid path set in a patient's vasculature, to convert the electrical signals to pressure wave form information, and to send the pressure wave form information to the monitoring control module.Type: GrantFiled: May 25, 2018Date of Patent: March 21, 2023Assignee: BAYER HEALTHCARE LLCInventors: Gerald Callan, Michael Spohn
-
COMBINATION OF AN AHR-INHIBITOR AND AN PD1-INHIBITOR ANTIBODY AND ITS USE IN THE TREATMENT OF CANCER
Publication number: 20230084899Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an AhR inhibitor, and component B being pembrolizumab or nivolumab. A further aspect of the present invention relates to combinations of three components, component A, component B, and component C; component A being an AhR inhibitor, component B being pembrolizumab or nivolumab, and component C being a further pharmaceutical agent. The present invention further relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment or prophylaxis of cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, kidney, head and neck, thyroid, parathyroid, and their distant metastases, lymphomas, sarcomas and leukemias.Type: ApplicationFiled: December 14, 2020Publication date: March 16, 2023Applicant: Bayer AktiengesellschaftInventor: Ilona GUTCHER -
Patent number: 11602591Abstract: A fluid delivery device includes: a fluid-filled cartridge comprising an outlet; a syringe comprising a substantially cylindrical syringe barrel having an open end and a fluid dispensing end; and a plunger rod configured to be received within the open end of the syringe barrel. The plunger rod comprises: a first end having a sealing member provided in sealing engagement with an inner wall of the syringe barrel such that a first syringe chamber is provided between the first end of the plunger rod and the fluid dispensing end of the syringe barrel; a second end extending out of the open end of the syringe barrel and having a cartridge-receiving chamber having a connection mechanism positioned therein for connecting the outlet of the cartridge thereto. The plunger rod also includes a fluid channel extending from the connection mechanism to the first end of the plunger rod.Type: GrantFiled: January 17, 2020Date of Patent: March 14, 2023Assignee: BAYER HEALTHCARE LLCInventor: Kevin P. Cowan